A M H Krebber1, F Jansen1, B I Witte2, P Cuijpers3, R de Bree4, A Becker-Commissaris5, E F Smit5, A van Straten3, A M Eeckhout6, A T F Beekman6, C R Leemans1, I M Verdonck-de Leeuw7. 1. Department of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam (CCA). 2. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam. 3. Department of Clinical Psychology, EMGO+ Institute for Health and Care Research, VU University, Amsterdam. 4. Department of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam (CCA) Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, Utrecht. 5. Department of Pulmonary Diseases. 6. Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. 7. Department of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam (CCA) Department of Clinical Psychology, EMGO+ Institute for Health and Care Research, VU University, Amsterdam im.verdonck@vumc.nl.
Abstract
BACKGROUND: This study aimed to evaluate the efficacy of stepped care (SC) targeting psychological distress in head and neck cancer (HNC) and lung cancer (LC) patients. PATIENTS AND METHODS: Patients with untreated distress [Hospital Anxiety and Depression Scale (HADS; HADS-D > 7, HADS-A > 7, or HADS-total > 14)] were randomized to SC (n = 75) or care-as-usual (CAU) (n = 81). SC consisted of watchful waiting, guided self-help, problem-solving therapy, and psychotherapy and/or psychotropic medication. The primary outcome measure was the HADS; secondary outcome measures were recovery rate, EORTC QLQ-C30, QLQ-HN35/QLQ-LC13, and IN-PATSAT32. Measures were assessed at baseline, after completion of care, and at 3, 6, 9, and 12 months follow-up. Linear mixed models, t-tests, and effect sizes (ES) were used to assess group differences. RESULTS:Patients with untreated distress were randomized to SC (n = 75) or care-as-usual (CAU) (n = 81). The course of psychological distress was better after SC compared with CAU (HADS-total, P = 0.005; HADS-A, P = 0.046; HADS-D, P = 0.007). The SC group scored better post-treatment (HADS-total, ES = 0.56; HADS-A, ES = 0.38; HADS-D, ES = 0.64) and at 9 months follow-up (HADS-total, ES = 0.42 and HADS-A, ES = 0.40). The recovery rate post-treatment was 55% after SC compared with 29% after CAU (P = 0.002), and 46% and 37% at 12 months follow-up (P = 0.35). Within SC, 28% recovered after watchful waiting, 34% after guided self-help, 9% after problem-solving therapy, and 17% after psychotherapy and/or psychotropic medication. The effect of SC was stronger for patients with a depressive or anxiety disorder compared with patients without such a disorder (HADS-total, P = 0.001; HADS-A, P = 0.003; HADS-D, P = 0.041). CONCLUSIONS:SC is effective and speeds up recovery among HNC and LC patients with untreated psychological distress. TRIAL REGISTRATION: Netherlands Trial Register (NTR1868).
RCT Entities:
BACKGROUND: This study aimed to evaluate the efficacy of stepped care (SC) targeting psychological distress in head and neck cancer (HNC) and lung cancer (LC) patients. PATIENTS AND METHODS: Patients with untreated distress [Hospital Anxiety and Depression Scale (HADS; HADS-D > 7, HADS-A > 7, or HADS-total > 14)] were randomized to SC (n = 75) or care-as-usual (CAU) (n = 81). SC consisted of watchful waiting, guided self-help, problem-solving therapy, and psychotherapy and/or psychotropic medication. The primary outcome measure was the HADS; secondary outcome measures were recovery rate, EORTC QLQ-C30, QLQ-HN35/QLQ-LC13, and IN-PATSAT32. Measures were assessed at baseline, after completion of care, and at 3, 6, 9, and 12 months follow-up. Linear mixed models, t-tests, and effect sizes (ES) were used to assess group differences. RESULTS:Patients with untreated distress were randomized to SC (n = 75) or care-as-usual (CAU) (n = 81). The course of psychological distress was better after SC compared with CAU (HADS-total, P = 0.005; HADS-A, P = 0.046; HADS-D, P = 0.007). The SC group scored better post-treatment (HADS-total, ES = 0.56; HADS-A, ES = 0.38; HADS-D, ES = 0.64) and at 9 months follow-up (HADS-total, ES = 0.42 and HADS-A, ES = 0.40). The recovery rate post-treatment was 55% after SC compared with 29% after CAU (P = 0.002), and 46% and 37% at 12 months follow-up (P = 0.35). Within SC, 28% recovered after watchful waiting, 34% after guided self-help, 9% after problem-solving therapy, and 17% after psychotherapy and/or psychotropic medication. The effect of SC was stronger for patients with a depressive or anxiety disorder compared with patients without such a disorder (HADS-total, P = 0.001; HADS-A, P = 0.003; HADS-D, P = 0.041). CONCLUSIONS: SC is effective and speeds up recovery among HNC and LC patients with untreated psychological distress. TRIAL REGISTRATION: Netherlands Trial Register (NTR1868).
Authors: Leeanne Nicklas; Mairi Albiston; Martin Dunbar; Alan Gillies; Jennifer Hislop; Helen Moffat; Judy Thomson Journal: BMC Health Serv Res Date: 2022-09-07 Impact factor: 2.908
Authors: Anouk S Schuit; Karen Holtmaat; Valesca van Zwieten; Eline J Aukema; Lotte Gransier; Pim Cuijpers; Irma M Verdonck-de Leeuw Journal: Front Psychol Date: 2021-04-22
Authors: Jessica R Bauman; Jessie R Panick; Thomas J Galloway; John A Ridge; Marcin A Chwistek; Molly E Collins; Leigh Kinczewski; Kathleen Murphy; Marie Welsh; Matthew A Farren; Mollie Clark Omilak; Jacqueline Kelly; Katherine A Schuster; Lauren A Lucas; Sheila Amrhein; Florence P Bender; Jennifer S Temel; Brian L Egleston; Areej El-Jawahri; Carolyn Y Fang Journal: J Palliat Med Date: 2021-04-13 Impact factor: 2.947
Authors: Anne-Marie H Krebber; Cornelia F van Uden-Kraan; Heleen C Melissant; Pim Cuijpers; Annemieke van Straten; Annemarie Becker-Commissaris; C René Leemans; Irma M Verdonck-de Leeuw Journal: Support Care Cancer Date: 2016-09-01 Impact factor: 3.603
Authors: Roy A Willems; Ilse Mesters; Lilian Lechner; Iris M Kanera; Catherine A W Bolman Journal: J Cancer Surviv Date: 2017-07-11 Impact factor: 4.442
Authors: Femke Jansen; Veerle M H Coupé; Simone E J Eerenstein; C René Leemans; Irma M Verdonck-de Leeuw Journal: Support Care Cancer Date: 2017-11-03 Impact factor: 3.603